Since a few years, ICIs targeting the programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) axis are used to treat cisplatin-ineligible patients with a PD-L1 positive tumor as well as patients that have progressed on first-line platinum-based chemotherapy. This evidence concerns the gene PDCD1 and neoplasm.